BOTHELL, Wash.--(BUSINESS WIRE)--MDRNA, Inc. (Nasdaq: MRNA) announced today positive in vivo efficacy data on its proprietary RNAi-based therapeutic for the treatment of multiple strains of influenza A virus in animal models. The in vivo data were presented by Shaguna Seth, Ph.D., Associate Director at MDRNA, Inc., at the XIV International Congress of Virology in Istanbul, Turkey.
